The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $20.65

Today's change+0.07 +0.34%
Updated August 18 1:27 PM EDT. Delayed by at least 15 minutes.
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $20.65

Today's change+0.07 +0.34%
Updated August 18 1:27 PM EDT. Delayed by at least 15 minutes.

Arena Pharmaceuticals Inc up (U.S.)$0.07

Arena Pharmaceuticals Inc is up today by (U.S.)$0.07 or 0.34% to (U.S.)$20.65. Shares have lost 1.81% over the last five days, but have gained 45.42% over the last year to date. This security has outperformed the S&P 500 by 14.58% during the last year.

Key company metrics

  • Open(U.S.) $20.47
  • Previous close(U.S.) $20.58
  • High(U.S.) $21.00
  • Low(U.S.) $20.36
  • Bid / Ask(U.S.) $20.64 / (U.S.) $20.68
  • YTD % change+45.42%
  • Volume160,793
  • Average volume (10-day)659,329
  • Average volume (1-month)1,816,563
  • Average volume (3-month)869,763
  • 52-week range(U.S.) $11.30 to (U.S.) $27.86
  • Beta1.39
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.59
Updated August 18 1:27 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue678519
Total other revenue--------
Total revenue678519
Gross profit437916
Total cost of revenue3363
Total operating expense28274729
Selling / general / administrative7879
Research & development18161217
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0--220
Other operating expenses, total--------
Operating income-21-2138-10
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-24-2238-12
Income after tax-24-2238-12
Income tax, total--------
Net income-23-2239-12
Total adjustments to net income--------
Net income before extra. items-23-2239-12
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-23-2239-12
Inc. avail. to common incl. extra. items-23-2239-12
Diluted net income-23-2239-12
Dilution adjustment----00
Diluted weighted average shares30242424
Diluted EPS excluding extraordinary itemsvalue per share-0.77-0.901.59-0.51
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.77-0.902.48-0.50